Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ORIC Oric Pharmaceuticals	$10.23 +2.0%	$10.36	$3.90 ▼ $14.67	$993.57M	1.69	1.09 million shs	711,530 shs
PHAR Pharming Group	$14.84 +1.7%	$11.22	$6.73 ▼ $17.08	$1.02B	0.02	6,398 shs	8,789 shs
PRQR ProQR Therapeutics	$2.25 +2.7%	$2.16	$1.07 ▼ $4.62	$236.73M	0.43	418,203 shs	152,458 shs
UPB Upstream Bio	$17.13 +2.2%	$13.84	$5.14 ▼ $29.46	$923.48M	N/A	354,639 shs	305,698 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ORIC Oric Pharmaceuticals	-2.24%	+3.51%	-9.15%	+21.43%	-1.38%
PHAR Pharming Group	+4.44%	+15.24%	+45.83%	+33.91%	+95.31%
PRQR ProQR Therapeutics	-0.90%	-0.90%	0.00%	+30.36%	+10.61%
UPB Upstream Bio	+0.36%	-5.52%	+19.97%	+83.17%	+1,675,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ORIC Oric Pharmaceuticals	4.7887 of 5 stars	4.5	3.0	4.4	2.6	3.3	0.6
PHAR Pharming Group	2.3482 of 5 stars	3.5	3.0	0.0	3.0	0.0	0.6
PRQR ProQR Therapeutics	2.7842 of 5 stars	3.6	5.0	0.0	3.4	0.0	0.0
UPB Upstream Bio	2.3229 of 5 stars	3.5	0.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ORIC Oric Pharmaceuticals	2.90	Moderate Buy	$17.63	72.29% Upside
PHAR Pharming Group	3.00	Buy	$30.00	102.16% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	255.56% Upside
UPB Upstream Bio	3.00	Buy	$56.50	229.83% Upside

Current Analyst Ratings Breakdown

Latest PRQR, UPB, ORIC, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ORIC Oric Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
8/14/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
8/13/2025	ORIC Oric Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/12/2025	ORIC Oric Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.34 per share	N/A
PHAR Pharming Group	$297.20M	3.42	$0.08 per share	188.48	$3.50 per share	4.24
PRQR ProQR Therapeutics	$16.49M	14.36	N/A	N/A	$0.72 per share	3.13
UPB Upstream Bio	$2.37M	389.65	N/A	N/A	$7.58 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ORIC Oric Pharmaceuticals	-$127.85M	-$1.89	N/A	N/A	N/A	N/A	-51.75%	-47.09%	11/11/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.13	N/A	494.67	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	11/6/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	-3,836.58%	-35.90%	-26.26%	11/6/2025 (Estimated)

Latest PRQR, UPB, ORIC, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	-$0.47	-$0.01	-$0.47	N/A	N/A
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million
8/6/2025	Q2 2025	UPB Upstream Bio	-$0.61	-$0.74	-$0.13	-$0.74	$0.32 million	$0.94 million
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ORIC Oric Pharmaceuticals	N/A	16.13	16.13
PHAR Pharming Group	0.38	2.79	2.07
PRQR ProQR Therapeutics	N/A	3.76	3.76
UPB Upstream Bio	N/A	38.27	38.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ORIC Oric Pharmaceuticals	95.05%
PHAR Pharming Group	0.03%
PRQR ProQR Therapeutics	32.65%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ORIC Oric Pharmaceuticals	6.82%
PHAR Pharming Group	2.07%
PRQR ProQR Therapeutics	8.40%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ORIC Oric Pharmaceuticals	80	97.12 million	90.50 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
UPB Upstream Bio	38	53.91 million	46.60 million	N/A

PRQR, UPB, ORIC, and PHAR Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Shares Down 5.4% - What's Next?

August 27 at 3:07 PM | marketbeat.com

Piper Sandler bestätigt 'Overweight'-Rating für Upstream Bio und sieht deutliches Kurspotenzial

August 26 at 3:38 PM | de.investing.com

Upstream Bio (NASDAQ:UPB) Shares Down 4.8% - Here's What Happened

August 20, 2025 | marketbeat.com

Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug

August 20, 2025 | msn.com

Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's Why

August 12, 2025 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Cut by William Blair

August 9, 2025 | marketbeat.com

Upstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

August 8, 2025 | finance.yahoo.com

Upstream Bio (UPB) Q2 R&D Soars 169%

August 6, 2025 | fool.com

Upstream Bio, Inc. reports Q2 results

August 6, 2025 | seekingalpha.com

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

August 6, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Stock Price Up 8.1% - Still a Buy?

July 31, 2025 | marketbeat.com

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Promising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory Conditions

July 28, 2025 | tipranks.com

Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP Treatment

July 28, 2025 | tipranks.com

Upstream Bio Inc. (UPB) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Upstream Bio begins phase 2 COPD trial for verekitug

July 10, 2025 | uk.investing.com

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic ...

July 8, 2025 | bakersfield.comB

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio

July 8, 2025 | quiverquant.comQ

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

July 8, 2025 | globenewswire.com

UPB Upstream Bio, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRQR, UPB, ORIC, and PHAR Company Descriptions

Oric Pharmaceuticals NASDAQ:ORIC

$10.23 +0.20 (+1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$10.23 0.00 (0.00%)

As of 05:42 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Pharming Group NASDAQ:PHAR

$14.84 +0.25 (+1.71%)

Closing price 03:58 PM Eastern

Extended Trading

$14.57 -0.27 (-1.81%)

As of 04:15 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NASDAQ:PRQR

$2.25 +0.06 (+2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$2.20 -0.04 (-2.00%)

As of 04:10 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Upstream Bio NASDAQ:UPB

$17.13 +0.37 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$17.80 +0.68 (+3.94%)

As of 04:48 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time